靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段申请上市 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
The Purpose of This Clinical Study is to Prove That the Test Drug (AJU-S56 5%) is Superior to the Control Drug After 24 Weeks of Administration to Patients Who Have Moderate or Severe Dry Eye Syndrome
This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.
A Phase 2 Multicenter, Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AJU-S56 in Patients With Dry Eye Disease
This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56) compared to control drug(vehicle) in Patients with Dry Eye Disease.
A Phase 2 Multicenter, Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease
This study is a randomized, double-blind, placebo-controlled phase 2 clinical trial to evaluate the efficacy and safety of GLH8NDE in patients with Dry Eye Disease.
100 项与 GL Pharm Tech Corp. 相关的临床结果
0 项与 GL Pharm Tech Corp. 相关的专利(医药)
100 项与 GL Pharm Tech Corp. 相关的药物交易
100 项与 GL Pharm Tech Corp. 相关的转化医学